6 results on '"Iwasaki R"'
Search Results
2. [A case of type 4 gastric cancer with peritoneal dissemination complicating venous thromboembolism treated effectively by combination of S-1 and warfarin].
- Author
-
Murayama Y, Sano I, Doi Y, Iwasaki R, Chatani T, Horiki M, Kitada M, Okuno M, Kondo S, Fukuda H, and Kashihara T
- Subjects
- Antineoplastic Combined Chemotherapy Protocols administration & dosage, Biopsy, Combined Modality Therapy, Drug Combinations, Female, Gastroscopy, Humans, Middle Aged, Neoplasm Staging, Oxonic Acid administration & dosage, Peritoneal Neoplasms diagnostic imaging, Peritoneal Neoplasms secondary, Quality of Life, Stomach Neoplasms complications, Stomach Neoplasms diagnostic imaging, Stomach Neoplasms pathology, Tegafur administration & dosage, Tomography, X-Ray Computed, Venous Thromboembolism complications, Warfarin administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Oxonic Acid therapeutic use, Peritoneal Neoplasms drug therapy, Stomach Neoplasms drug therapy, Tegafur therapeutic use, Venous Thromboembolism drug therapy, Warfarin therapeutic use
- Abstract
A 49-year-old female patient was admitted to our hospital for a type 4 gastric cancer with peritoneal dissemination. Two courses of paclitaxel (PTX), and eight courses of S-1 were carried out. Although a partial response was obtained, she had complications with a deep venous thromboembolism (DVT) and pulmonary embolism (PE) during the treatment. Heparin, followed by warfarin, was useful to treat the embolism. After the venous thromboembolism (VTE) disappeared, combination therapy with S-1 and warfarin were started, and the quality of life (QOL) of this patient was maintained for about one year. Fine monitoring of the international normalized ratio (INR) was required in order to prevent side effects of blood coagulation by S-1 and warfarin coadministration. This case suggests that the combination therapy of S-1 and warfarin may be a safe and effective treatment able to prolong time to progression against a type 4 gastric cancer with VTE.
- Published
- 2010
3. [A case of elderly metastatic breast cancer with a complete response to treatment with capecitabine and cyclophosphamide].
- Author
-
Iida S, Furukawa K, Yokoyama T, Yanagihara K, Iwasaki R, Noguchi T, Tsuchiya S, Sugisaki Y, Naito Z, and Tajiri T
- Subjects
- Aged, Antimetabolites, Antineoplastic administration & dosage, Antineoplastic Agents, Alkylating administration & dosage, Breast Neoplasms pathology, Capecitabine, Carcinoma, Ductal, Breast pathology, Cyclophosphamide administration & dosage, Deoxycytidine administration & dosage, Drug Administration Schedule, Female, Fluorouracil administration & dosage, Humans, Lymphatic Metastasis, Neoplasm Metastasis, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Breast Neoplasms drug therapy, Carcinoma, Ductal, Breast drug therapy, Deoxycytidine analogs & derivatives, Fluorouracil analogs & derivatives
- Abstract
We report a case of elderly metastatic breast cancer with a complete response to the treatment with XC (X: capecitabine and C: cyclophosphamide). A 78-year-old woman, who presented with left breast cancer, underwent pectoralis-preserving mastectomy when she was 76 years old. Pathological findings were as follows: invasive ductal carcinoma (scirrhous type), pT1c (2.0 cm), n (1/10), ly3, v1, ER (-), PgR (-), HER2: score 1. After one year and a half, a left supraclavicular lymph node metastasis, a left interpectoral lymph node metastasis, and mediastinal lymph nodes metastasis were noted. Capecitabine and cyclophosphamide were administered as first-line chemotherapy. After 8 cycles, all metastases responded, and this therapy is now being continued (19 cycles) on an outpatient basis. The complete response has continued for nine months. XC therapy can be the first-line chemotherapy for elderly metastatic breast cancer patients since it has been effective and no serious side effects have been encountered while maintaining quality of life.
- Published
- 2007
4. Phase 1/11 study of bi-weekly irinotecan plus cisplatin in the treatment of advanced gastric cancer.
- Author
-
Koizumi W, Kurihara M, Satoh A, Takiuchi H, Tanabe S, Shimada K, Iwasaki R, and Saigenji K
- Subjects
- Adult, Aged, Anemia chemically induced, Camptothecin adverse effects, Cisplatin adverse effects, Diarrhea chemically induced, Drug Administration Schedule, Feasibility Studies, Female, Humans, Irinotecan, Male, Maximum Tolerated Dose, Middle Aged, Neutropenia chemically induced, Stomach Neoplasms mortality, Survival Rate, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Camptothecin administration & dosage, Camptothecin analogs & derivatives, Cisplatin administration & dosage, Stomach Neoplasms drug therapy
- Abstract
Objectives: To conduct a phase I/II study of irinotecan with cisplatin to establish a recommended dose, and assess the safety, efficacy and feasibility of this regimen in unresectable advanced or recurrent gastric cancer., Patients and Methods: In the phase I portion of the study, patients received a fixed dose of cisplatin (30 mg/m2) with escalating doses of irinotecan, ranging from 30 mg/m2 to 70 mg/m2, on days 1 and 15. In the phase II portion of the study, 40 patients were evaluated for response and safety at the recommended dose., Results: Eighteen patients were enrolled in the phase I study. Dose-limiting toxicity (diarrhea and neutropenia) appeared at the irinotecan dose of 70 mg/m2. Therefore, the recommended irinotecan dose was 60 mg/m2. In the phase II study, 40 patients received cisplatin (30 mg/m2) plus irinotecan (60 mg/m2). Twenty-five out of 40 patients had received prior chemotherapy. The median number of cycles was 3.5. The response rate was 32.5% (13/40) overall, and 53.3% (8/15) in patients without prior chemotherapy. The median time to tumor progression (TTP) was 162 days. The median survival time was 288 days. Four patients (10%) developed grade 4 neutropenia and 3 patients (7.5%) developed grade 4 anemia. The only observed non-hematological toxicity at grade 3 or higher was diarrhea, seen in 2.5% (1/40) of the patients., Conclusion: Bi-weekly administration of irinotecan and cisplatin is safe and active for the management of unresectable advanced or recurrent gastric cancer.
- Published
- 2005
5. Sequence-dependence of cisplatin and 5-fluorouracil in advanced and recurrent gastric cancer.
- Author
-
Koizumi W, Kurihara M, Hasegawa K, Chonan A, Kubo Y, Maekawa R, Iwasaki R, Sasai T, Fukuyama Y, Ishikawa K, Miyoshi K, Yasutake K, and Hayakawa M
- Subjects
- Adult, Aged, Aged, 80 and over, Antimetabolites, Antineoplastic administration & dosage, Antineoplastic Agents administration & dosage, Disease Progression, Female, Humans, Male, Middle Aged, Recurrence, Stomach Neoplasms mortality, Time Factors, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Cisplatin administration & dosage, Fluorouracil administration & dosage, Stomach Neoplasms drug therapy
- Abstract
This randomized controlled clinical trial was designed to compare the safety and effectiveness of different sequences of treatment with cisplatin (CDDP) and 5-fluorouracil (5-FU) in patients with unresectable advanced and post-operative recurrent gastric cancer. Patients with unresectable advanced or post-operative recurrent gastric cancer were randomly assigned by a registration center to group A or B. Group A received CDDP (80 mg/m(2)) as a continuous 2-h intravenous infusion on day 1 and 5-FU (700 mg/m(2)) as a continuous intravenous infusion on days 2-5. Group B was given 5-FU (700 mg/m(2)) as a continuous intravenous infusion on days 1-4, followed by CDDP (80 mg/m(2)) as a continuous 2-h intravenous infusion on day 5. Each course of chemotherapy was repeated every 28 days. A total of 74 patients were enrolled. One patient died accidentally, and 5 could not be evaluated. Response was assessable in 68 patients. The response rate was 31.3% (10/32) in group A as compared with 13.9% (5/36) in group B. Although the response rate was higher in Group A, the difference was not significant (p=0.085). The response rate in patients with diffuse type tumors was significantly lower in group B. There was no difference between the groups in response among patients with intestinal type tumors. The median overall survival was 239 and 174 days and time to progression was 175 and 140 days in group A and group B, respectively. Although there were trends toward longer survival and time to progression in group A, the differences between the groups were not statistically significant. There was also no difference in the type or incidence of adverse reactions. The results of this controlled study indicate that the overall response rate was slightly but not significantly higher in patients who received CDDP before 5-FU. Among patients with diffuse type tumors, the response rate was significantly lower when 5-FU was administered before CDDP. Our results suggest that CDDP should be given before 5-FU in patients with gastric cancer when treated with a combination of CDDP and 5-FU.
- Published
- 2004
6. [A case of gastric malignant lymphoma with perforation during chemotherapy].
- Author
-
Ono K, Matsumura S, Sakamoto K, Kobayashi S, Kamano T, and Iwasaki R
- Subjects
- Colonic Neoplasms pathology, Cyclophosphamide administration & dosage, Doxorubicin administration & dosage, Humans, Lymphoma, Large B-Cell, Diffuse pathology, Male, Methotrexate administration & dosage, Middle Aged, Neoplasm Invasiveness, Pancreatic Neoplasms pathology, Prednisolone administration & dosage, Rupture, Spontaneous, Splenic Neoplasms pathology, Stomach Neoplasms pathology, Vincristine administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Lymphoma, Large B-Cell, Diffuse drug therapy, Stomach Neoplasms drug therapy, Stomach Rupture etiology
- Abstract
A 54-year-old male was admitted for loss of appetite lasting for about 3 months. The patient was diagnosed as malignant lymphoma in the stomach invading directly the pancreas, spleen and transverse colon. Chemotherapy, two cycles of VEPA.M, was selected as the initial treatment. After the first cycle of chemotherapy, the patient was discharged temporarily. During the second cycle, on an ambulant basis, the patient suddenly complained of severe pain and distension in the abdomen. Through the X-ray examination of the chest, free air was demonstrated in the bilateral subphrenic spaces. The patient was diagnosed as perforation of the gastrointestinal tract. Subsequently, total gastrectomy was performed. Pathological examination revealed no malignant cells in the stomach wall. It is suggested that the perforation was caused by weakening of the stomach wall following chemotherapy.
- Published
- 1997
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.